Wortmannin

Catalog No.S2758 Synonyms: KY 12420

Wortmannin Chemical Structure

Molecular Weight(MW): 428.43

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.

Size Price Stock Quantity  
USD 110 In stock
USD 170 In stock
USD 270 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

5 Customer Reviews

  • L3.6pl cells at 6,000 cells per well were incubated in MEM with 5% FBS in triplicate in a 96-well culture plate and then treated alone with 5 umol/L BMS-777607, 10 umol/L wortmannin, or with BMS-777607 in combination with individual inhibitors. Polyploidy was examined under BK71 Olympus microscope and photographed 72 hours after treatment.

    Mol Cancer Ther 2014 13(1), 37-48. Wortmannin purchased from Selleck.

    The effects of KITL on the differentiation of stem Leydig cells. Seminiferous tubules were cultured in the presence of various concentrations of KITL (K) without (C) or with PI3K inhibitor wortmannin (W) for 21 days. Panel A, KITL (0-100 ng/ml); Panel B, KITL (K) alone or with W (100 nM), K1 = KITL 1 ng/ml, K100 = 100 ng/ml. Medium testosterone (T) levels were measured. Mean ± SEM, n = 4-8. Identical letters indicate no significant difference between two groups at P < 0.05. W:Wortmannin

    Mol Cell Endocrinol, 2017, 444:1-8. Wortmannin purchased from Selleck.

  • Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

    Int J Mol Sci 2013 14(9), 17304-18. Wortmannin purchased from Selleck.

  • Cell growth inhibition of non-small cell lung carcinoma (NSCLC) by inhibitor of phosphoinositide 3-kinases (PI3Ks) Wortmannin. NCI-H460 and its multi-drug resistant (MDR) counterpart NCI-H460/R were subjected to Wortmannin. According to the results obtained, the effect of Wortmannin is dependent on the existence of MDR in the range of tested concentrations.

    2014 Dr.Milica Pesic from Institute for Biological Research. Wortmannin purchased from Selleck.

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Targets
PI3K [3]
(Cell-free assay)
DNA-PK [12]
(Cell-free assay)
ATM [12]
(Cell-free assay)
MLCK [1]
(Cell-free assay)
3 nM 16 nM 150 nM 170 nM
In vitro

The inhibition of MLCK by Wortmannin is not affected by calmodulin or peptide substrat, while reduced by high concentration of ATP. Wortmannin directly interacts with the catalytic domain of MLCK and leads to an irreversible loss of the enzyme activity. Wortmannin has no inhibitory to cAMP-dependent protein kinase, cGMP-dependent protein kinase, and calmodulin-dependent protein kinase II, and has little effect on protein kinase C activity. [1] Wortmannin inhibits N-formylmethionyl-leucylphenylalanine (fMLP)-stimulated PtdInsP3 (phosphatidylinositol 3,4,5-trisphosphate) formation with IC50 of 5 nM and this inhibition is completely abolished when pretreated with 100 nM Wortmannin in human neutrophils, with increased PtdInsP2 levels and no effects on cellular PtdInsP and PtdIns contents. Wortmannin could develop oscillatory changes in F-actin content and does not inhibit fMLP-stimulated actin polymerization in neutrophils. [2] Wortmannin irreversibly inhibits phosphatidylinositol 3-kinase (PI3-kinase) activity with binding to the 110-kDa protein (IC50 of 3 nM) and has no effect PI4-kinase in RBL-2H3 cells. Wortmannin also inhibits both Fc epsilon RI-mediated histamine secretion and leukotriene release, with no effect on the activation of the tyrosine kinase Lyn. [3] Wortmannin completely abolishes the insulin-induced hexose uptake in isolated rat adipocytes at 0.1 μM, without impairing isoproterenol-stimulated lipolytic activity. [4] Wortmannin suppresses insulin-induced production of nitric oxide by 50% at 500 nM in human umbilical vein endothelial cells, which is in response to IGF-1. [5] Wortmannin suppresses DNA double strand break (DSB) repair and has no effect on DSB levels or the kinetics of single strand break (SSB) repair in Chinese hamster ovary cells at 50 μM. Wortmannin could potentiate ionizing radiation (IR)-induced cytotoxicity with no toxicity by itself. [6] Wortmannin inhibits polo-like kinase (PLK1) activity IC50 of 24 nM in intact G2/M-arrested cells. [7] Wortmannin increases Toll-like receptor (TLR)-mediated accumulation of IL-6 in human macrophages with EC50 of 50 nM. Meanwhile Wortmannin significantly enhances TLR-mediated inducible nitric-oxide synthase (iNOS) expression and nitrite accumulation in mouse macrphages. Wortmannin activates the nuclear factor-κB and up-regulates the cytokine mRNA production. [8] Wortmannin also inhibits Polo-like kinase (PlK) 1 and PlK3, which play important roles in mitosis. Wortmannin treatment could lead to a reduction in phosphorylation of p53 on serine 20 induced by DNA damage. [9] Wortmannin suppresses hyaluronan-induced Akt phosphorylation and cell motility/migration in SW1990 cells. [10]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
A459 MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVqyMlUh|ryP NVLtc4Y2OS12IHS= M3jXZ2ROW09? NWHnenFS\W6qYX7j[ZMh[2WubDDndo94fGhiaX7obYJqfGmxbjD0doVifG2nboSge4l1cCC2YX3vfIln\W5? MnrXNlU1QTB|OEO=
H1703 NVfMXFdmT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTmNI44Oi53IN88US=> M2TmXlEuPCCm NXT6XHNLTE2VTx?= MYTlcohidmOnczDj[YxtKGe{b4f0bEBqdmirYnn0bY9vKHS{ZXH0cYVvfCC5aYToJJRidW:6aX\lci=> MUeyOVQ6ODN6Mx?=
HUVECs Mn\QR5l1d3SxeHnjbZR6KEG|c3H5 Mm\MNVAxKG6P NYDaOIZiOjRiaB?= NIezVIRifHSnboXheIV{KHSqZTDhZpJw\2G2aY\lJIVn\mWldIOgc4Yh[2GueXPvd4lvKG:wIG\STU1qdmS3Y3XkJIN6fG:2b4jpZ4l1gQ>? NEP5RVkzPTR3MEG4Oi=>
APRE-19 NXfHZmtHSXCxcITvd4l{KEG|c3H5 M4H3fVUh|ryP NEXxUGwzPCCq NIjWSGVi[m:uaYPo[ZMhTkycLX3l[IlifGWmIIDyc{1{fXK4aY\hcE9idnSrLXHwc5B1d3OrczDhZ5Rqfmm2eR?= MkDYNlU{Ojl4MUe=
MDA-MB-231 MnvJRZBweHSxc3nzJGF{e2G7 NYGyZmFMOcLizszNxsA> NYrUUIxQPDhiaB?= MofISG1UVw>? NFv2V4Vl\WO{ZXHz[ZMhfGinIHPlcIwhe3W{dnn2ZYwhfHKnYYTl[EB4cXSqIEK1JO69VSCxZjDGNUBweiCIMjFCpC=> NIDCR|EzPTNyMEmzNi=>
MCF7 M{HiOWZ2dmO2aX;uJGF{e2G7 MlfONVAxKG6P MnLJNlQhcA>? MUflcIlucW6jdHXzJGUzNWmwZIXj[YQhSVKHLVz1Z{Bi[3Srdnn0fS=> M1rrZ|I2OTd{NUW3
HT-29  MnPqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYr3WFJzOS53wrFCuW0> Mnv3PVYhcA>? MYjk[YNz\WG|ZYOgZ4VtdCCpcn;3eIghf2irY3igZ4FvKGKnIHnubIljcXSnZDDifUBMYU6D NI\5TJAzPTBzMkGyNy=>
MO59K  MmS5R5l1d3SxeHnjbZR6KEG|c3H5 NH\tXYo2yqEQvF2= MV63JIQ> M4PpRmROW09? M{nzfYVvcGGwY3XzJJRp\SCleYTveI95cWOrdImgc4Yh\XSxcH;zbYRmKG:{IHPpd5Bt[XSrbh?= M3:1cFI1QTV|NU[x
MO59J M4nxWmN6fG:2b4jpZ4l1gSCDc4PhfS=> NXHxfJVTPcLizszN NXi2[mZ4PyCm M2G3WGROW09? NH2xV4RmdmijbnPld{B1cGViY4n0c5RwgGmlaYT5JI9nKGW2b4Dvd4ll\SCxcjDjbZNxdGG2aX6= Mo\aNlQ6PTN3NkG=
MO59K  M4PhWWFxd3C2b4Ppd{BCe3OjeR?= MVWxNEDPxE1? NWPOS|gxOjRiaB?= M4HjT2ROW09? MnHTbY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv NGXFNJMzPDl3M{W2NS=>
MO59J Mk\RRZBweHSxc3nzJGF{e2G7 M3y3bFExKM7:TR?= MkLZNlQhcA>? MXrEUXNQ MlP0bY5kemWjc3XzJJRp\SCGU1KgcIV3\WxiaX7keYNm\CCkeTDleI9xd3OrZHWgc5Ih[2m|cHzheIlv NGjpPIUzPDl3M{W2NS=>
HepG2 MVjGeY5kfGmxbjDBd5NigQ>? NX6wNJhoOTByIH7N NFnINVkxNjViaB?= M4jFOmROW09? NU\zc3lk[myxY3vzJG1CNWmwZIXj[YQhSWu2IIDoc5NxcG:{eXzheIlwdg>? MojCNlQ5PjN|NUC=
A549  M3zBVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjFN{DDvU4EoB?= M1\4dlIhcA>? M13SbZN2eHC{ZYPz[ZMheGWvZYTy[Zhm\C2rbnT1Z4VlKEGtdDDhcoQhT1ONM98yJIFkfGm4YYTpc44tKFNvcHjhd4Uh[XK{ZYP0MEBk\WyuIHHwc5B1d3OrczDhcoQh[2G|cHHz[U0{KGGldHn2ZZRqd25? NH\0b4UzPDh2N{i2Ny=>
A549  Mon0SpVv[3Srb36gRZN{[Xl? NFf4VmUyOMLizsztxsA> MVexOkBp MlfQSG1UVw>? NXPIfmhpdW:mdXzheIV{KHSqZTDJRXYhemWybHnjZZRqd25iYX7kJINifXOnczDy[ZRmdnSrb36gc4YhVlBiaX6geIhmKG63Y3zleZMv MYWyOFgxOjFzMR?=
SK-N-LO M1TEWmZ2dmO2aX;uJGF{e2G7 NEPreIgyODBibl2= NF\CdHgxNjViaB?= M2CyWoRm[3KnYYPld{B1cGVic4TpcZVt[W62IHXm[oVkfHNib3[gcY9zeGirbnWgc44hSWu2IIDoc5NxcG:{eXzheIlwdg>? NH\1OIozPDZ3NE[wOi=>
HL-60 Ml20SpVv[3Srb36gRZN{[Xl? NXvZVFhiOC5zwrFOwG0> NIjMUJo4OiCq MkDyZoxw[2u|IHThd4F1cW6rYj3pcoR2[2WmIHPlcIwh\GmoZnXy[Y51cWG2aX;u MVyyOFYxPzJ5Mx?=
HepG2  M1vFbWZ2dmO2aX;uJGF{e2G7 MVqyNFAhdk1? MWWwMlUhcA>? M4XET4F1fGWwdXH0[ZMhTm:6TzDwbI9{eGixconsZZRqd25? M{LCPFI1PTN3MUmy
H520 M1TDOGZ2dmO2aX;uJGF{e2G7 M2j4dFExyqEQvF2= NV;VcZlqOSCq M{G2RmROW09? MWrk[YNz\WG|ZYOgZ4VtdHWuYYKgdIhwe3Cqbz3BT3QheHKxdHXpckBt\X[nbIO= NHjVT|AzPDR2N{mzOS=>
H1975 NFTVbYhHfW6ldHnvckBCe3OjeR?= M3\PZlExyqEQvF2= NVzMflNCOSCq MWHEUXNQ MoDJ[IVkemWjc3XzJINmdGy3bHHyJJBpd3OyaH:tRWtVKHC{b4TlbY4hdGW4ZXzz MVOyOFQ1Pzl|NR?=
MG-63 MYXBdI9xfG:|aYOgRZN{[Xl? MnL1NVAhyrWP NXnndVVXOTJiaB?= NE[3VndmdmijbnPld{BFWC2rbnT1Z4VlKGGyb4D0c5Nqew>? M4m4b|I1OzV6M{Cx
5637 M3qz[mFxd3C2b4Ppd{BCe3OjeR?= M4LaeVExyqEQvF2= M{Pj[|QxKG2rbh?= MXfy[ZZmenOnczDwNlFYSUZzIHX4dJJme3Orb36sJGNFUyCneIDy[ZN{cW:wLDDhcoQh[2WubDDpcohq[mm2aX;uJIlv\HWlZXSgZpkh\nWlb3nkZY4> NUTQPWo6OjR|M{O4Olg>
HEK-293 MYnGeY5kfGmxbjDBd5NigQ>? NXnsZo5FOTVybl2= MV[xOkBp M3;VWmROW09? MWLk[YNz\WG|ZYOgR3JVKGGldHn2bZR6 NInSb4gzPDN{NEO2Oi=>
SW480  MmrvSpVv[3Srb36gRZN{[Xl? MUixOVBvVQ>? M4TQblIxKGh? M1\CZmROW09? MYDy[YR2[2W|IHPlcIx2dGG{IHHjZ5VufWyjdHnvckBw\iEQsj3jZZRmdmmw M4roV|I1OzJ2M{[2
HepG2 MVnGeY5kfGmxbjDBd5NigQ>? M{K0blExOCCwTR?= NFGyZ5AzPCCq M{\4S4F1fGWwdXH0[ZMhfGinIHPvcI9vcWW|IH;mJJRp\SC2dX3vdkBk\WyuczD3bZRpKHWycnXneYxifGmxbjDv[kBCc3Rz MoTwNlQzQTd3MUC=
HCT 116  NXjKWpNwTnWwY4Tpc44hSXO|YYm= MmDXNVAxKG6P MWGyOEBp MVTheJRmdnWjdHXzJJRp\SClb3zvcolmeyCxZjD0bIUhfHWvb4KgZ4VtdHNid3n0bEB2eHKnZ4XsZZRqd25ib3[gRYt1OQ>? M4XDZlI1Ojl5NUGw
BEL/FU M2CwOGZ2dmO2aX;uJGF{e2G7 NGDqVlUyKG2P MnnQNlQhcA>? M2qxcoRm[3KnYYPld{Bxem:2ZXnuJIxmfmWuczDv[kB1cGViUFmzT{9Cc3RicHH0bJdigQ>? MUGyOFI{OjB7OR?=
Huh7  M3fCN2Z2dmO2aX;uJGF{e2G7 MlnTN:Kh|ryP M{DSSFEhcA>? MV;y[YR2[2W|IITo[UB3cXK3czDlcpRzgSCrboTvJJRp\SClZXzsdy=> NWj4bpo2OjRzOESxPVY>
A-375 NF;BN2pCeG:ydH;zbZMhSXO|YYm= M1PKUVQwQCEQvF2= Mn\FNlQhcA>? NGKwO2RmdmijbnPld{BVWkGLTD3pcoR2[2WmIHHwc5B1d3Orc9Mg MUWyOFEyOzF5Mx?=
A-375-TS  NHnOXJRCeG:ydH;zbZMhSXO|YYm= MU[0M|gh|ryP M1jZOlI1KGh? NXzuPJpH\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> Mn;KNlQyOTNzN{O=
Mel-HO NY\oTnJYSXCxcITvd4l{KEG|c3H5 MWK0M|gh|ryP MX6yOEBp NYrxTYVV\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M{m5UlI1OTF|MUez
Mel-HO-TS MnHxRZBweHSxc3nzJGF{e2G7 M4DNUlQwQCEQvF2= MYqyOEBp NWXjdYZ6\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> M3fZVVI1OTF|MUez
MeWo NELxTYdCeG:ydH;zbZMhSXO|YYm= NGXXcWw1NzhizszN NEnmNnMzPCCq MoPx[Y5p[W6lZYOgWHJCUUxvaX7keYNm\CCjcH;weI9{cXQEoB?= MWqyOFEyOzF5Mx?=
Mel-2a NVfkPWtDSXCxcITvd4l{KEG|c3H5 MkXwOE85KM7:TR?= MUWyOEBp NWDpO5ht\W6qYX7j[ZMhXFKDSVytbY5lfWOnZDDhdI9xfG:|aYRCpC=> MUSyOFEyOzF5Mx?=
MDA-MB-231 NUDLRmdSTnWwY4Tpc44hSXO|YYm= MoTyNQKBmzRyMDDuUS=> MkfYOEBp M4nycJN2eHC{ZYPz[ZMhSWu2IIDoc5NxcG:{eXzheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? MXuyNlkxPjJ3OR?=
MDA-MB-231 NGjS[3dHfW6ldHnvckBCe3OjeR?= MVu0NFAhdk1? NFK4TYI1KGh? NHP4ZZZl\WO{ZXHz[ZMhVU2SLUmgZY5lKEmOLUigdJJwfGWrbjDpckBiKGSxc3Wt[IVx\W6mZX70JI1idm6nch?= MXuyNlkxPjJ3OR?=
Jurkat MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGn1bo8xNjJ3LUGuNlUh|ryP MnfSNlQwPDhiaB?= Ml\RSG1UVw>? MkfVbY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIlvKGKxdHigeIlu\S1iYX7kJIRwe2VvIHTldIVv\GWwdDDtZY5v\XJ? NGnwe5MyQTd3N{G4OS=>
Namalwa MlPZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3jwNlAvOjVvMT6yOUDPxE1? NXuwVGM2OjRxNEigbC=> NYnl[3NFTE2VTx?= NIHYSJBqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44hcW5iYn;0bEB1cW2nLTDhcoQh\G:|ZT2g[IVx\W6mZX70JI1idm6nch?= MYmxPVc2PzF6NR?=
Jurkat NFT0VIhCeG:ydH;zbZMhSXO|YYm= MX2wMlI2NTFwMkWg{txO MVWyOE81QCCq MXfEUXNQ NFrIR3JqdmS3Y3XzJINmdGxiYYDvdJRwe2m|IHnuJIJwfGhidHnt[U0h[W6mIHTvd4UuKGSncHXu[IVvfCCvYX7u[ZI> MlTCNVk4PTdzOEW=
Namalwa MYXBdI9xfG:|aYOgRZN{[Xl? NYDsR5VOOC5{NT2xMlI2KM7:TR?= NX7ycWk1OjRxNEigbC=> MmXBSG1UVw>? NV\hUJZwcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDpckBjd3SqIITpcYUuKGGwZDDkc5NmNSCmZYDlcoRmdnRibXHucoVz NEDuRWcyQTd3N{G4OS=>
K562 NGnoU2FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnfXNlQhcA>? NITTVY1KSzVyPUK1xtExNjF2IH7N Ml\VNVk3PjJ|NkG=
SW1990 MWfGeY5kfGmxbjDBd5NigQ>? NWK4SGdmOC5yMT2xJO69VQ>? MUKxJIg> NFXCO25qdmirYnn0d{BJSS2rbnT1Z4VlKEGtdDDwbI9{eGixconsZZRqd25? NXvvXWRyOTl2NkmwNlA>
RT112  NYDre2hVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUGxNOKh|ryP NUThU2hpOjRiaB?= M1;ISGROW09? M{ezboRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MXqxPFc5Pzh|Mh?=
MHG-U1 NFjmWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUGxNOKh|ryP M2DufFI1KGh? NWXJeYlkTE2VTx?= M3rDUYRm[3KnYYPld{B1cGVicILvdI9zfGmxbjDv[kBIOi:PIHPlcIx{ MonwNVg4QDd6M{K=
SMMC-7721 MV\BdI9xfG:|aYOgRZN{[Xl? MVKyNFDDqG6P MXOyOEBp NEP1e5ZqdmO{ZXHz[ZMhS0i[LXnu[JVk\WRiYYDvdJRwe2m| NX\zcIlwOTd3NUexPVE>
SMMC-7721 MYfGeY5kfGmxbjDBd5NigQ>? Ml\GNlAxyqCwTR?= M{THc|I1KGh? NVnEXFF[fXBvcnXneYxifGW|IN8yNUw1T1RzIHX4dJJme3Orb36= M1zMeFE4PTV5MUmx
HeLa MWfGeY5kfGmxbjDBd5NigQ>? M1PtXVExOMLibl5CpC=> M3jIOlEhcA>? NGn3Ro9idHSncoOgeIhmKG2xcoDoc4xw\3lib3[geIhmKHS{YX7z[oVzemmwIILlZ5lkdGmwZzDjc41x[XK2bXXueC=> Mlr2NVY5QTB7MUW=
MRC5VI NWWyZnFDTnWwY4Tpc44hSXO|YYm= NFfOTJcyOi53IH3N M4fYV|AvPSCq MWDEUXNQ M4Xrb4Fjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh Ml3FNVYzOjd|OUS=
AT5BIVA NI\lTlNHfW6ldHnvckBCe3OjeR?= MXqxNk42KG2P NGTKV|AxNjViaB?= MkL6SG1UVw>? NFfzd5Vi[m:uaYPo[ZMhfGinIGPldlQ4Oy:WaIKzNFjDqHCqb4PwbI9zgWyjdHnvckBw\iCDa4TQT2LDqA>? MYmxOlIzPzN7NB?=
M059J M4TZZ2Z2dmO2aX;uJGF{e2G7 M4LLNlEzNjVibV2= M4DhS|AvPSCq NEftR2dFVVOR MoT4ZYJwdGm|aHXzJJRp\SCVZYK0O|MwXGi{M{C4xsBxcG:|cHjvdplt[XSrb36gc4YhSWu2UFvCxsA> MnXrNVYzOjd|OUS=
HeLa NGXsfmpHfW6ldHnvckBCe3OjeR?= MYexNk42KG2P MkfWNE42KGh? M4TUT2ROW09? M{LjZoFjd2yrc3jld{B1cGViU3XyOFc{N1SqckOwPOKheGixc4Doc5J6dGG2aX;uJI9nKEGtdGDLRuKh NYLZbpRiOTZ{MkezPVQ>
N2a M{CwRmFxd3C2b4Ppd{BCe3OjeR?= M1\t[|AvOS1zMDFOwG0> NUjF[YpqOiCq MY\pcoR2[2W|IHTlZ5Jm[XOnZDDj[YxtKH[rYXLpcIl1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? MnTVNVU5PDJ5Nke=
Jurkat  NGr0d2dMcW6jc3WgRZN{[Xl? NUTafHplUUN3MDDv[kAzPCCwTR?= MWCxOVY3PDVzOR?=

... Click to View More Cell Line Experimental Data

In vivo Wortmannin inhibits peritoneal metastasis of SW1990 in mice at 1 mg/kg, without any weight loss. [10] Wortmannin inhibits phosphatidylinositide 3-kinase-protein kinase B (PKB)/Akt phosphorylation in both normal tissues (lung, heart and brain homogenates) and tumor tissue in mice, without mortality or acute toxicity at 0.7 mg/kg. Combination with LY188011, Wortmannin significantly increases apoptosis and inhibit tumor growth in orthotopic tumor, while both monotherapy could not. [11]

Protocol

Animal Research:[11]
+ Expand
  • Animal Models: Human pancreatic adenocarcinoma cells PK1 are injected both s.c. and orthotopically into SCID mice.
  • Formulation: Dissolved at 0.4 mg/mL in DMSO, and diluted with 0.9% NaCl before use
  • Dosages: 0.175, 0.35, and 0.7 mg/kg
  • Administration: Injected by i.v.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 85 mg/mL (198.39 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
5%DMSO+corn oil
For best results, use promptly after mixing.
11mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 428.43
Formula

C23H24O8

CAS No. 19545-26-7
Storage powder
Synonyms KY 12420

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Tags: buy Wortmannin | Wortmannin supplier | purchase Wortmannin | Wortmannin cost | Wortmannin manufacturer | order Wortmannin | Wortmannin distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID